Anthropic Claude Finds ART Enzyme System
Analysis based on 8 articles · First reported Sep 23, 2026 · Last updated Sep 24, 2026
The announcement reinforces the narrative that AI can accelerate basic scientific research, likely lifting sentiment toward AI and gene-editing related equities while raising competitive pressure on traditional biotech R&D pipelines. Concrete market effects remain limited because the finding is preliminary, unpublished in peer-reviewed form, and of unknown function.
Anthropic unveiled the first discovery from its molecular biology lab: a previously unknown enzyme system, dubbed ART, identified by its Claude AI model. According to the company, roughly 950 Claude-powered software agents combed a DNA sequence database for 21 hours, finding more than 200,000 genes for one enzyme type and selecting 20 for closer review, work Anthropic says would take an expert scientist weeks or months. One agent spotted short repeating DNA fragments in bacteria-infecting viruses next to genes for a known enzyme and a mystery protein, a setup resembling CRISPR. Anthropic chief Dario Amodei cited the finding in video remarks to the United Nations Security Council, calling it preliminary but potentially a new gene editing mechanism with gene therapy applications. The results were published as a preprint and have not been peer reviewed. Feng Zhanwen, a CRISPR pioneer and professor at the Massachusetts Institute of Technology and the Broad Institute, called the identification genuinely intriguing and said it merits further investigation. Amodei also said a Stanford University team independently described a comparable but distinct system. Anthropic said its lab team, formed in the spring and based in the San Francisco Bay Area, does not handle pathogens capable of infecting humans, and all experiments are carried out by human scientists.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard